Skip to main content

Interleukin 2 in Cancer Therapy

Buy Article:

$63.00 plus tax (Refund Policy)

Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With introduction of novel kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines for treatment of cancer there is an increased interest in combining these therapeutic strategies with IL-2. Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: (Eastern Coopera-tive Oncology Group Scale; (IL-2); (IL-2R); Cancer Therapy; HIGH DOSE IL-2; IL-2 therapy; Interferon; Interferon-alpha; Interleukin-2; Metastatic Melanoma; Phase II clinical trial; Phase III clinical trial; Renal Cell Cancer; T-cells; TNF alpha and beta; anemia; biochemotherapy (BCT); cardiac stress test; cell carcinoma; chills; confusion; diarrhea; eosinophilia; eosinophilic myocarditis; erythroderma; fever; hepatic enzymes elevation; immunotherapy; inhibitors; kidney cancer; lethargy; lymphopenia; malig-nant melanoma; malignant melanoma; melanoma; metastatic kidney cancer; nausea; phosphorylation; renal cell carcinoma; thrombocytopenia; transient fever; tumor infiltrating lymphocytes (TILs); tyrosine kinase

Document Type: Research Article

Publication date: 01 October 2010

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more